RNA vs CABA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

RNA

61.7
AI Score
VS
RNA Wins

CABA

47.5
AI Score

Investment Advisor Scores

RNA

62score
Recommendation
BUY

CABA

48score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric RNA CABA Winner
Net Income -36.82M -94.53M RNA
Operating Income -39.90M -96.32M RNA
ROE -17.2% -44.9% RNA
ROA -13.1% -36.8% RNA
Total Assets 280.51M 256.73M RNA
Cash 72.33M 225.10M CABA
Current Ratio 8.73 5.79 RNA

Relative Price Performance (Last 90 Days)

RNA 1M: -44.0% · 3M: -39.4% CABA 1M: -47.9% · 3M: -38.2%

Current Technical Phase

RNA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -10.2%), weak momentum, RSI 24

RSI (14): 23.6 · Price: $7.88

CABA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -6.2%), weak momentum, RSI 25

RSI (14): 25.4 · Price: $1.86

Fundamentals Snapshot

Metric RNA CABA
Market Cap — —
Forward P/E -1.0 -1.6
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.2% 0.0%
Gross Margin -0.6% —
Operating Margin -7.5% 0.0%
EPS -5.44 -1.38
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, RNA is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.